1H NMR Metabolomics Analysis of Glioblastoma Subtypes

Background: Unpredictable clinical behavior of glioblastoma multiforme suggests distinct molecular subtypes. Results: Metabolic profiles of different glioblastoma lines indicate distinct subtypes correlated with gene expression differences. Conclusion: A subset of metabolites can be used to distinguish between four subtypes of glioblastomas. Significance: Metabolic profiling of cancers provides a way for subtype determination with possible diagnostic and prognostic applications. Glioblastoma multiforme (GBM) is the most common form of malignant glioma, characterized by unpredictable clinical behaviors that suggest distinct molecular subtypes. With the tumor metabolic phenotype being one of the hallmarks of cancer, we have set upon to investigate whether GBMs show differences in their metabolic profiles. 1H NMR analysis was performed on metabolite extracts from a selection of nine glioblastoma cell lines. Analysis was performed directly on spectral data and on relative concentrations of metabolites obtained from spectra using a multivariate regression method developed in this work. Both qualitative and quantitative sample clustering have shown that cell lines can be divided into four groups for which the most significantly different metabolites have been determined. Analysis shows that some of the major cancer metabolic markers (such as choline, lactate, and glutamine) have significantly dissimilar concentrations in different GBM groups. The obtained lists of metabolic markers for subgroups were correlated with gene expression data for the same cell lines. Metabolic analysis generally agrees with gene expression measurements, and in several cases, we have shown in detail how the metabolic results can be correlated with the analysis of gene expression. Combined gene expression and metabolomics analysis have shown differential expression of transporters of metabolic markers in these cells as well as some of the major metabolic pathways leading to accumulation of metabolites. Obtained lists of marker metabolites can be leveraged for subtype determination in glioblastomas.

[1]  Paola Pisani,et al.  Genetic Pathways to Glioblastoma , 2004, Cancer Research.

[2]  Dan C. Tulpan,et al.  MetaboHunter: an automatic approach for identification of metabolites from 1H-NMR spectra of complex mixtures , 2011, BMC Bioinformatics.

[3]  V. Govindaraju,et al.  Proton NMR chemical shifts and coupling constants for brain metabolites , 2000, NMR in biomedicine.

[4]  Holly T. Sullivan,et al.  The Prostate 68 : 620 ^ 628 ( 2008 ) TheMetabolitesCitrate , Myo-Inositol , and Spermine Are PotentialAge-IndependentMarkers of Prostate Cancer inHumanExpressed Prostatic Secretions , 2008 .

[5]  S. Gabriel,et al.  Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. , 2010, Cancer cell.

[6]  David S. Wishart,et al.  HMDB: a knowledgebase for the human metabolome , 2008, Nucleic Acids Res..

[7]  C. Brennan,et al.  Glioblastoma Subclasses Can Be Defined by Activity among Signal Transduction Pathways and Associated Genomic Alterations , 2009, PloS one.

[8]  E. Ingenito,et al.  Epidermal growth factor receptor and claudin‐2 participate in A549 permeability and remodeling: Implications for non‐small cell lung cancer tumor colonization , 2009, Molecular carcinogenesis.

[9]  Mark Noble,et al.  Characteristic metabolic profiles revealed by 1H NMR spectroscopy for three types of human brain and nervous system tumours , 1995, NMR in biomedicine.

[10]  Nabil Belacel,et al.  Fuzzy J-Means and VNS methods for clustering genes from microarray data , 2004, Bioinform..

[11]  M. Daly,et al.  PGC-1α-responsive genes involved in oxidative phosphorylation are coordinately downregulated in human diabetes , 2003, Nature Genetics.

[12]  Dan Tulpan,et al.  1H NMR metabolomics combined with gene expression analysis for the determination of major metabolic differences between subtypes of breast cell lines , 2011 .

[13]  R. Tibshirani,et al.  Significance analysis of microarrays applied to the ionizing radiation response , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[14]  S. Ronen,et al.  17-allyamino-17-demethoxygeldanamycin treatment results in a magnetic resonance spectroscopy-detectable elevation in choline-containing metabolites associated with increased expression of choline transporter SLC44A1 and phospholipase A2 , 2010, Breast Cancer Research.

[15]  Adam Dicker,et al.  The contribution of epidermal growth factor receptor (EGFR) signaling pathway to radioresistance in human gliomas: a review of preclinical and correlative clinical data. , 2004, International journal of radiation oncology, biology, physics.

[16]  Nabil Belacel,et al.  NMR metabolic analysis of samples using fuzzy K‐means clustering , 2009, Magnetic resonance in chemistry : MRC.

[17]  S. Williams,et al.  Cell type-specific fingerprinting of meningioma and meningeal cells by proton nuclear magnetic resonance spectroscopy. , 1995, Cancer research.

[18]  Guido Kroemer,et al.  Tumor cell metabolism: cancer's Achilles' heel. , 2008, Cancer cell.

[19]  T. Mak,et al.  Regulation of cancer cell metabolism , 2011, Nature Reviews Cancer.

[20]  J. Pouysségur,et al.  Hypoxia signalling controls metabolic demand. , 2007, Current opinion in cell biology.

[21]  Pablo Tamayo,et al.  Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[22]  R. Kauppinen,et al.  A metabolomics perspective of human brain tumours , 2007, The FEBS journal.

[23]  Jing Li,et al.  New Bioinformatics Resources For Metabolomics , 2006, Pacific Symposium on Biocomputing.

[24]  Chi V Dang,et al.  Rethinking the Warburg effect with Myc micromanaging glutamine metabolism. , 2010, Cancer research.

[25]  J R Griffiths,et al.  Classification of tumour 1H NMR spectra by pattern recognition , 1992, NMR in biomedicine.

[26]  Stephan Frank,et al.  MAP kinase-interacting kinase 1 regulates SMAD2-dependent TGF-β signaling pathway in human glioblastoma. , 2011, Cancer research.